#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	14782	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2587	704.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1686	1686	C	982	C,A	980,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24956	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4027	772.8	0	.	n	.	0	T695C	SNP	695	695	T	1246	1246	C	931	C,A	929,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24956	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4027	772.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1888	1888	A	1074	A,G,T,C	1069,3,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24956	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4027	772.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2522	2522	C	806	C,A	805,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24956	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4027	772.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2596	2596	A	784	A,C	782,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24956	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4027	772.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	3148	3148	C	869	C,T,A	867,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.Neisseria_meningitidis_H44_76_v1_00541	folP.Neisseria_meningitidis_H44_76_v1_00541	1	1	539	1980	folP	858	858	98.7	folP.l15.c4.ctg.1	1875	131.6	0	.	p	.	0	Q7R	NONSYN	19	21	CAG	559	561	CGG	155;158;157	C;G;G	155;158;157	.	.
folP.Neisseria_meningitidis_H44_76_v1_00541	folP.Neisseria_meningitidis_H44_76_v1_00541	1	1	539	1980	folP	858	858	98.7	folP.l15.c4.ctg.1	1875	131.6	0	.	p	.	0	I115V	NONSYN	343	345	ATC	883	885	GTC	188;188;190	G;T,G;C	188;187,1;190	.	.
folP.Neisseria_meningitidis_H44_76_v1_00541	folP.Neisseria_meningitidis_H44_76_v1_00541	1	1	539	1980	folP	858	858	98.7	folP.l15.c4.ctg.1	1875	131.6	0	.	p	.	0	P200T	NONSYN	598	600	CCC	1138	1140	ACC	230;228;225	A,T;C;C	229,1;228;225	.	.
folP.Neisseria_meningitidis_H44_76_v1_00541	folP.Neisseria_meningitidis_H44_76_v1_00541	1	1	539	1980	folP	858	858	98.7	folP.l15.c4.ctg.1	1875	131.6	0	.	p	.	0	E279D	NONSYN	835	837	GAA	1375	1377	GAC	144;141;137	G;A;C	144;141;137	.	.
folP.Neisseria_meningitidis_H44_76_v1_00541	folP.Neisseria_meningitidis_H44_76_v1_00541	1	1	539	1980	folP	858	858	98.7	folP.l15.c4.ctg.1	1875	131.6	1	SNP	p	R230S	1	.	.	688	690	AGC	1228	1230	AGC	219;222;223	A;G;C,A	219;222;222,1	folP.Neisseria_meningitidis_H44_76_v1_00541:1:1:R230S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4924	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3879	158.3	1	SNP	p	S91F	0	.	.	271	273	TCC	802	804	TCC	180;179;179	T;C;C,A	180;179;178,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4924	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3879	158.3	1	SNP	p	D95G	0	.	.	283	285	GAC	814	816	GAC	188;190;190	G,A;A,T;C	187,1;189,1;190	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4924	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3879	158.3	1	SNP	p	D95N	0	.	.	283	285	GAC	814	816	GAC	188;190;190	G,A;A,T;C	187,1;189,1;190	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_K_01388	mtrR.WHO_K_01388	1	1	27	1974	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1841	133.9	1	SNP	p	G45D	1	.	.	133	135	GAC	748	750	GAC	205;204;205	G;A,T;C	205;203,1;205	mtrR.WHO_K_01388:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1086	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c17.ctg.1	1358	99.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4838	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3311	181.9	1	SNP	p	D86N	0	.	.	256	258	GAC	731	733	GAC	219;225;227	G;A;C	219;225;227	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4838	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3311	181.9	1	SNP	p	S87R	0	.	.	259	261	AGT	734	736	AGT	224;223;224	A,C;G;T	222,2;223;224	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4838	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3311	181.9	1	SNP	p	S87W	0	.	.	259	261	AGT	734	736	AGT	224;223;224	A,C;G;T	222,2;223;224	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4838	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3311	181.9	1	SNP	p	S87I	0	.	.	259	261	AGT	734	736	AGT	224;223;224	A,C;G;T	222,2;223;224	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4838	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3311	181.9	1	SNP	p	S88P	0	.	.	262	264	TCC	737	739	TCC	225;230;231	T;C;C,A	225;230;230,1	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4178	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3155	165.0	0	.	p	.	0	H611Y	NONSYN	1831	1833	CAC	2410	2412	TAC	200;202;202	T,C;A;C,A	199,1;202;201,1	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4178	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3155	165.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1807	1809	GGC	206;203;204	G;G;C,G,A	206;203;202,1,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3970	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2807	176.3	1	SNP	p	A311V	0	.	.	931	933	GCA	1482	1484	GCA	215;215;218	G;C,A;A	215;214,1;218	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3970	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2807	176.3	1	SNP	p	I312M	0	.	.	934	936	ATC	1485	1487	ATC	220;220;220	A,C;T,G;C	219,1;219,1;220	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3970	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2807	176.3	1	SNP	p	V316P	0	.	.	946	948	GTG	1497	1499	GTG	229;231;231	G;T,C;G	229;230,1;231	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3970	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2807	176.3	1	SNP	p	V316T	0	.	.	946	948	GTG	1497	1499	GTG	229;231;231	G;T,C;G	229;230,1;231	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3970	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2807	176.3	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2001	2003	ACC	220;220;222	A,G;C,T,G;C	219,1;218,1,1;222	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3970	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2807	176.3	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2055	2057	GCG	228;226;227	G,A;C;G,C	227,1;226;225,2	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3970	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2807	176.3	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2055	2057	GCG	228;226;227	G,A;C;G,C	227,1;226;225,2	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3970	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2807	176.3	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2178	2180	GGC	219;215;217	G;G,A;C	219;212,3;217	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3970	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2807	176.3	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2187	2189	GGC	218;220;221	G,T;G,T;C,A	217,1;219,1;220,1	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3970	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2807	176.3	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2205	2207	CCG	237;234;235	C,T;C;G,T	236,1;234;232,3	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	5542	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3562	193.8	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1824	1826	CTG	221;220;220	C;T;G	221;220;220	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2404	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2341	128.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	827	827	C	181	C	181	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2758	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1752	194.2	0	.	p	.	0	G38E	NONSYN	112	114	GGA	564	566	GAA	248;247;249	G;A,C;A	248;246,1;249	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2758	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1752	194.2	0	.	p	.	0	S46G	NONSYN	136	138	AGC	588	590	GGC	253;254;254	G,A;G;C	252,1;254;254	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2758	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1752	194.2	0	.	p	.	0	E48G	NONSYN	142	144	GAA	594	596	GGA	255;255;254	G;G;A,C	255;255;253,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2758	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1752	194.2	0	.	p	.	0	T87A	NONSYN	259	261	ACT	711	713	GCT	226;226;223	G;C;T	226;226;223	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2758	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1752	194.2	0	.	p	.	0	T89S	NONSYN	265	267	ACC	717	719	AGC	224;223;223	A;G;C	224;223;223	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2758	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1752	194.2	0	.	p	.	0	.	MULTIPLE	358	359	AA	809	810	CG	188;186	C;G	188;186	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2758	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1752	194.2	0	.	p	.	0	.	MULTIPLE	361	362	GA	812	814	CAG	192;192;192	C;A;G,T	192;192;191,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2758	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1752	194.2	0	.	p	.	0	N122K	NONSYN	364	366	AAC	816	818	AAA	196;197;201	A;A;A	196;197;201	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2758	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1752	194.2	0	.	p	.	0	K143E	NONSYN	427	429	AAA	879	881	GAA	237;238;239	G;A,C;A	237;237,1;239	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2758	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1752	194.2	0	.	p	.	0	V151A	NONSYN	451	453	GTA	903	905	GCA	245;247;245	G,C;C;A	244,1;247;245	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2758	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1752	194.2	0	.	p	.	0	A215T	NONSYN	643	645	GCT	1095	1097	ACT	231;228;228	A;C;T	231;228;228	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2758	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1752	194.2	0	.	p	.	0	I218M	NONSYN	652	654	ATA	1104	1106	ATG	229;230;229	A;T;G	229;230;229	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2758	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1752	194.2	0	.	p	.	0	T256A	NONSYN	766	768	ACA	1218	1220	GCA	227;227;227	G;C;A	227;227;227	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2758	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1752	194.2	0	.	p	.	0	W257T	NONSYN	769	771	TGG	1221	1223	ACG	226;225;224	A;C;G	226;225;224	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2758	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1752	194.2	0	.	p	.	0	S258G	NONSYN	772	774	AGT	1224	1226	GGG	229;231;230	G;G,T;G	229;229,2;230	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2758	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1752	194.2	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1227	1229	GTT	226;228;227	G,T;T;T	225,1;228;227	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2758	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1752	194.2	0	.	p	.	0	L279V	NONSYN	835	837	TTA	1287	1289	GTA	202;200;201	G;T;A	202;200;201	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2758	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1752	194.2	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1326	1328	ACT	206;207;207	A;C;T,G	206;207;206,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2758	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1752	194.2	0	.	p	.	0	H294D	NONSYN	880	882	CAT	1332	1334	GAT	215;212;214	G;A;T	215;212;214	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2758	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1752	194.2	0	.	p	.	0	Y298H	NONSYN	892	894	TAC	1344	1346	CAC	230;232;233	C;A;C	230;232;233	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2758	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1752	194.2	1	SNP	p	G120K	1	.	.	358	360	AAG	809	811	CGG	188;186;187	C;G;G	188;186;187	porB1b.WHO_L_01891c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2758	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1752	194.2	1	SNP	p	A121D	1	.	.	361	363	GAC	812	815	CGC	192;192;193	C;G,T;C	192;191,1;193	porB1b.WHO_L_01891c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2758	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1752	194.2	1	SNP	p	D121N	0	.	.	361	363	GAC	812	815	CGC	192;192;193	C;G,T;C	192;191,1;193	porB1b.WHO_L_01891c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9854	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5328	230.7	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2234	2236	AAT	251;251;250	A;A,C;T,G	251;250,1;249,1	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1500	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1481	126.4	1	SNP	p	V57M	1	.	.	169	171	ATG	702	704	ATG	249;250;253	A;T;G	249;250;253	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
